ATLANTA--(BUSINESS WIRE)--July 31, 2013--MedAssets, Inc. (NASDAQ: MDAS) today announced results for its second quarter and six-month periods ended June 30, 2013. Second quarter results are summarized in the table below:

($ in millions, except per share)	2Q’13		2Q’12		% Change
Net Revenue:
Spend and Clinical Resource Mgmt (SCM)	$	105.3	$	102.1	3.1	%
Revenue Cycle Management (RCM)		65.4		60.9	7.5
Total Net Revenue		170.7		163.0	4.7
Net income		5.1		2.3	125.9
Earnings per share (EPS) – diluted		0.08		0.04	100.0
Non-GAAP adjusted EBITDA		52.5		49.0	7.2
Non-GAAP adjusted EPS - diluted	$	0.30	$	0.28	7.1
Weighted average shares – diluted		60.7		58.7	3.4	%

Total net revenue for the second quarter of 2013 increased 4.7% to $170.7 million from $163.0 million for the second quarter of 2012. Net revenue in the SCM segment increased 3.1% to $105.3 million from net revenue of $102.1 million for the second quarter of 2012, due primarily to group purchasing net administrative fee growth, partially offset by an expected year-over-year decrease in performance-related fees. Net revenue in the RCM segment increased 7.5% to $65.4 million from $60.9 million for the second quarter of 2012 as technology-related revenue increased 6.5% while services-related revenue grew 9.7%.

Total net revenue for the first half of 2013 increased 9.8% to $343.6 million from $312.9 million for the first half of 2012. Net revenue in the SCM segment grew 9.9% to $214.8 million from net revenue of $195.4 million for the first half of 2012. Net revenue in the RCM segment increased 9.6% to $128.8 million from $117.5 million for the first half of 2012 as technology-related revenue grew 7.3% and services-related revenue increased 14.9%.

Total non-GAAP adjusted EBITDA was $52.5 million, or 30.8% of total net revenue, for the second quarter of 2013, a 7.2% increase from total non-GAAP adjusted EBITDA of $49.0 million, or 30.1% of total net revenue, for the second quarter of 2012. The 71 basis point margin increase was due to higher RCM segment margin and relatively flat corporate expenses, partially offset by an expected year-over-year decrease in performance-related fees.

For the first half of 2013, total non-GAAP adjusted EBITDA was $114.2 million, or 33.2% of total net revenue, a 19.7% increase over total non-GAAP adjusted EBITDA of $95.4 million, or 30.5% of total net revenue, for the first half of 2012.

The Company reported net income for the second quarter of 2013 of $5.1 million, or $0.08 per share, compared to net income of $2.3 million, or $0.04 per share, for the second quarter of 2012.

Non-GAAP adjusted EPS (defined as EPS excluding non-cash acquisition-related intangible amortization and depreciation, non-cash share-based compensation, certain acquisition and integration-related expenses and non-recurring items on a tax-adjusted basis) was $0.30 per share for the second quarter of 2013, a 7.1% increase when compared with non-GAAP adjusted EPS of $0.28 per share for the second quarter of 2012.

Net income for the first half of 2013 was $12.8 million, or $0.21 per share, versus net income of $2.0 million, or $0.03 per share, for the first half of 2012. Non-GAAP adjusted EPS was $0.71 per share for the first half of 2013, a 39.2% increase over non-GAAP adjusted EPS of $0.51 per share for the first half of 2012.

Cash provided by operating activities in the first half of 2013 was $67.6 million versus $62.7 million for the same period of 2012. Non-GAAP free cash flow (defined as cash provided by operating activities less purchases of property, equipment and software and capitalized software development costs) increased 25.4% to $43.4 million versus $34.6 million for the first six months of 2012. The Company prepaid an additional $40.0 million of its Term Loan B in the second quarter of 2013 along with its scheduled principal payments. Its balance sheet at June 30, 2013 included $821.5 million in total bank and bond debt, net of cash and cash equivalents. Total net debt equates to leverage of approximately 3.6 times non-GAAP adjusted EBITDA for the trailing twelve-month period.

At June 30, 2013, MedAssets rolling 12-month non-GAAP contracted revenue estimate was $616.8 million (SCM segment - $378.4 million; RCM segment - $238.4 million), a year-over-year increase of 2.2%. Non-GAAP contracted revenue is the Company’s estimate of contractually committed revenue to be generated under existing client contracts in the forward 12-month period.

Note: The live webcast will include a slide presentation, a copy of which is available on http://ir.medassets.com in the “Events & Presentations” section in conjunction with today’s event.

MedAssets (NASDAQ: MDAS) partners with healthcare providers to improve their financial strength by implementing revenue cycle, spend and clinical resource management solutions that help capture revenue, control cost, improve margins and cash flow, increase regulatory compliance, and optimize operational efficiency. MedAssets serves more than 4,200 hospitals and 122,000 non-acute healthcare providers. The company currently manages more than $50 billion in supply spend and touches over $365 billion in gross patient revenue annually through its revenue cycle solutions. For more information, go to www.medassets.com.

In order to provide investors with greater insight, promote transparency and allow for a more comprehensive understanding of the information used by management and the board of directors in their financial and operational decision-making, the Company supplements its condensed consolidated financial statements presented on a GAAP basis herein with the following non-GAAP financial information: gross fees; gross administrative fees; revenue share obligation; EBITDA; adjusted EBITDA; adjusted EBITDA margin; adjusted net income; diluted adjusted EPS; free cash flow; and contracted revenue. Reconciliations of these non-GAAP measures to their most directly comparable GAAP measures, where possible, are included in the accompanying financial schedules. Also, see "Use of Non-GAAP Financial Measures" following the financial schedules for more information.

This Press Release contains forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995, and include the intent, belief or current expectations of the Company and its management team with respect to the Company’s future business operations that include, but are not limited to: 2013 financial guidance, revenue growth and other financial projections and forecasts; and the Company’s ability to successfully integrate and capitalize on synergies associated with acquisitions. Any forward-looking statements are not guarantees of future performance, involve risks and uncertainties, and actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those contemplated by the forward-looking statements in this Press Release include, but are not limited to: failure to realize improvements in performance, efficiency and profitability; failure to complete anticipated sales under negotiations; failure to successfully implement revenue backlog; lack of revenue growth; customer losses; and adverse developments with respect to the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this Press Release can also be found in the Company’s Risk Factor disclosures in its Form 10-K for the year ended December 31, 2012 filed with the Securities and Exchange Commission and available at http://ir.medassets.com. The Company disclaims any responsibility to update any forward-looking statements.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

In 000s, except per share data	Three Months Ended					Six Months Ended
	June 30,					June 30,
	2013		2012		% Change	2013		2012		% Change
Revenue:
Administrative fees, net	$	70,502	$	66,695	5.7%	$	147,021	$	132,111	11.3%
Other service fees		100,240		96,315	4.1%		196,558		180,789	8.7%

Total net revenue		170,742		163,010	4.7%		343,579		312,900	9.8%

Operating expenses:
Cost of revenue (inclusive of certain amortization expense)		37,496		34,730	8.0%		71,764		66,013	8.7%
Product development expenses		7,975		6,638	20.1%		16,476		13,560	21.5%
Selling and marketing expenses		20,285		19,178	5.8%		34,027		33,726	0.9%
General and administrative expenses		57,199		56,574	1.1%		115,819		110,410	4.9%
Acquisition and integration-related expenses		1,435		2,028	-29.2%		9,465		3,277	188.8%
Depreciation		9,876		7,281	35.6%		19,053		13,695	39.1%
Amortization of intangibles		16,115		18,481	-12.8%		32,616		37,411	-12.8%

Total operating expenses		150,381		144,910	3.8%		299,220		278,092	7.6%

Operating income		20,361		18,100	12.5%		44,359		34,808	27.4%
Other income (expense):
Interest expense		(12,381)		(16,871)	-26.6%		(23,730)		(34,050)	-30.3%
Other income		276		228	21.1%		317		335	-5.4%

Income before income taxes		8,256		1,457	466.6%		20,946		1,093	1816.4%
Income tax expense (benefit)		3,172		(794)	nm		8,158		(919)	nm

Net income		5,084		2,251	125.9%		12,788		2,012	535.6%

Basic net income per share		0.09		0.04	125.0%		0.22		0.04	450.0%

Diluted net income per share	$	0.08	$	0.04	100.0%	$	0.21	$	0.03	600.0%

Weighted average shares — basic		59,387		57,174			59,198		57,102
Weighted average shares — diluted		60,665		58,678	3.4%		60,628		58,637	3.4%

CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)

	June 30,		December 31,
In 000s, except share and per share amounts	2013		2012

ASSETS
Current assets
Cash and cash equivalents	$	716	$	13,734
Accounts receivable, net of allowances of $2,458 and $3,046 as of June 30, 2013 and December 31, 2012, respectively		95,569		96,346
Deferred tax asset, current		5,113		11,126
Prepaid expenses and other current assets		21,545		21,791

Total current assets		122,943		142,997

Property and equipment, net		151,994		134,361
Other long term assets
Goodwill		1,027,847		1,027,847
Intangible assets, net		297,547		330,163
Other		41,626		42,869
Other long term assets		1,367,020		1,400,879

Total assets	$	1,641,957	$	1,678,237

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable	$	28,808	$	25,487
Accrued revenue share obligation and rebates		78,087		74,274
Accrued payroll and benefits		29,819		40,085
Other accrued expenses		15,427		14,145
Current portion of deferred revenue		52,292		55,756
Current portion of notes payable		15,500		15,500
Current portion of finance obligation		244		233

Total current liabilities		220,177		225,480

Notes payable, less current portion		481,750		544,500
Bonds payable		325,000		325,000
Finance obligation, less current portion		8,916		9,046
Deferred revenue, less current portion		14,676		14,393
Deferred tax liability		117,037		125,394
Other long term liabilities		15,081		801

Total liabilities		1,182,637		1,244,614

Commitments and contingencies

Stockholders’ equity
Common stock, $0.01 par value, 150,000,000 shares authorized; 61,032,000 and 59,324,000 shares issued and outstanding as of June 30, 2013 and December 31, 2012, respectively		610		593
Additional paid in capital		701,323		688,431
Accumulated deficit		(242,613)		(255,401)

Total stockholders’ equity		459,320		433,623

Total liabilities and stockholders’ equity	$	1,641,957	$	1,678,237

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

	Six Months Ended
In 000s	June 30,		June 30,
	2013		2012

Operating activities:
Net income	$	12,788	$	2,012

Adjustments to reconcile net income from continuing operations to net cash provided by operating activities:
Bad debt expense		-		275
Depreciation		20,222		14,512
Amortization of intangibles		32,616		37,689
Impairment of assets		2,403		-
(Gain) loss on sale of assets		(123)		338
Noncash stock compensation expense		7,422		5,015
Excess tax benefit from exercise of equity awards		(3,035)		(295)
Amortization of debt issuance costs		1,908		3,791
Noncash interest expense, net		239		270
Deferred income tax benefit		(2,560)		(1,384)

Changes in assets and liabilities		(4,296)		470

Cash provided by operating activities		67,584		62,693

Investing activities:
Purchases of property, equipment, and software		(5,328)		(7,892)
Capitalized software development costs		(18,861)		(20,208)

Cash used in investing activities		(24,189)		(28,100)

Financing activities:
Borrowings from revolving credit facility		-		55,000
Repayment of notes payable		(62,750)		(28,175)
Repayment of finance obligations		(338)		(338)
Payment of deferred purchase consideration		-		(120,136)
Excess tax benefit from exercise of equity awards		3,035		295
Issuance of common stock, net of offering costs		3,640		1,796
Purchase of treasury shares		-		(600)

Cash used in financing activities		(56,413)		(92,158)

Net decrease in cash and cash equivalents		(13,018)		(57,565)
Cash and cash equivalents, beginning of period		13,734		62,947

Cash and cash equivalents, end of period	$	716	$	5,382

SUPPLEMENTAL REVENUE REPORTING

RECONCILIATION OF GROSS FEES (A NON-GAAP MEASURE) TO NET REVENUE

(UNAUDITED)

In 000s

Three Months Ended June 30,

2013

2012

% Change

Non-GAAP gross administrative fees

115,488

107,512

7.4%

Other service fees

100,240

96,315

4.1%

Non-GAAP gross fees

215,728

RSO %

203,827

RSO %

5.8%

Non-GAAP revenue share obligation (RSO)

(44,986)

39.0%

(40,817)

38.0%

10.2%

Net revenue

170,742

163,010

4.7%

In 000s

Six Months Ended June 30,

2013

2012

% Change

Non-GAAP gross administrative fees

236,124

212,016

11.4%

Other service fees

196,558

180,789

8.7%

Non-GAAP gross fees

432,682

RSO %

392,805

RSO %

10.2%

Non-GAAP RSO

(89,103)

37.7%

(79,905)

37.7%

11.5%

Net revenue

343,579

312,900

9.8%

SUPPLEMENTAL SEGMENT REPORTING

RECONCILIATION OF SELECTED NON-GAAP MEASURES TO GAAP MEASURES

(UNAUDITED)

In 000s

Three Months Ended June 30,

2013

2012

% Change

Net revenue

Spend and Clinical Resource Management (SCM)

105,308

102,115

3.1%

Revenue Cycle Management (RCM)

65,434

60,895

7.5%

Total net revenue

170,742

163,010

4.7%

Non-GAAP Adjusted EBITDA

% margin

SCM

42,942

40.8%

44,558

43.6%

-3.6%

RCM

17,022

26.0%

12,079

19.8%

40.9%

Corporate

(7,427)

(7,631)

-2.7%

Total non-GAAP Adjusted EBITDA

52,537

30.8%

49,006

30.1%

7.2%

In 000s

Six Months Ended June 30,

2013

2012

% Change

Net revenue

SCM

214,816

195,380

9.9%

RCM

128,763

117,520

9.6%

Total net revenue

343,579

312,900

9.8%

Non-GAAP Adjusted EBITDA

% margin

SCM

96,654

45.0%

86,506

44.3%

11.7%

RCM

31,712

24.6%

23,697

20.2%

33.8%

Corporate

(14,183)

(14,791)

-4.1%

Total non-GAAP Adjusted EBITDA

114,183

33.2%

95,412

30.5%

19.7%

SUPPLEMENTAL REPORTING OF ADJUSTED EBITDA
RECONCILIATION OF SELECTED NON-GAAP MEASURES TO GAAP MEASURES
(UNAUDITED)

In 000s	Three Months Ended June 30,						Six Months Ended June 30,
	2013			2012			2013			2012

Net income	$	5,084		$	2,251		$	12,788		$	2,012

Depreciation		9,876			7,281			19,053			13,695
Depreciation (included in cost of revenue)		571			407			1,169			817
Amortization of intangibles		16,115			18,481			32,616			37,411
Amortization of intangibles (included in cost of revenue)		-			139			-			278
Interest expense, net		12,382			16,866			23,731			34,045
Income tax expense (benefit)		3,172			(794	)		8,158			(919	)

Non-GAAP EBITDA	$	47,200		$	44,631		$	97,515		$	87,339

Share-based compensation		4,011			2,456			7,422			5,015
Rental income from capitalized building lease		(109	)		(109	)		(219	)		(219	)
Acquisition and integration-related expenses		1,435			2,028			9,465			3,277

Non-GAAP Adjusted EBITDA	$	52,537		$	49,006		$	114,183		$	95,412

SUPPLEMENTAL NET INCOME AND EARNINGS PER SHARE REPORTING
RECONCILIATION OF SELECTED NON-GAAP MEASURES TO GAAP MEASURES
(UNAUDITED)

	Three Months Ended June 30,						Six Months Ended June 30,
In 000s, except per share data	2013			2012			2013			2012

Net income	$	5,084		$	2,251		$	12,788		$	2,012

Pre-tax non-cash, acquisition-related intangible amortization and depreciation		16,589			19,093			33,564			38,635
Pre-tax non-cash, share-based compensation		4,011			2,456			7,422			5,015
Pre-tax acquisition and integration-related expenses		1,435			2,028			9,465			3,277
Tax effect on pre-tax adjustments ^a		(8,814	)		(9,430	)		(20,180	)		(18,770	)

Non-GAAP adjusted net income	$	18,305		$	16,398		$	43,059		$	30,169

Income Per Share (EPS) - diluted	$	0.08		$	0.04		$	0.21		$	0.03

Pre-tax non-cash, acquisition-related intangible amortization and depreciation		0.27			0.33			0.55			0.66
Pre-tax non-cash, share-based compensation		0.07			0.04			0.12			0.09
Pre-tax acquisition and integration-related expenses		0.02			0.03			0.16			0.06
Tax effect on pre-tax adjustments ^a		(0.14	)		(0.16	)		(0.33	)		(0.33	)

Non-GAAP adjusted EPS - diluted	$	0.30		$	0.28		$	0.71		$	0.51

Weighted average shares - diluted (in 000s)		60,665			58,678			60,628			58,637

SUPPLEMENTAL 2013 ADJUSTED EBITDA GUIDANCE
RECONCILIATION OF SELECTED NON-GAAP MEASURES TO GAAP MEASURES
(UNAUDITED)

	Guidance Range for
	Twelve Months Ending
In 000s	December 31, 2013
	(Low)			(High)

Net Income	$	22,900		$	26,600

Depreciation		41,200			42,000
Depreciation (included in cost of revenue)		2,200			2,200
Amortization of intangibles, acquisition-related		62,700			62,700
Interest expense, net		48,100			49,100
Income tax expense		15,200			17,700

Non-GAAP EBITDA		192,300			200,300

Share-based compensation		15,600			15,600
Acquisition and integration-related expenses		9,500			9,500
Rental income from capitalized building lease		(400	)		(400	)

Non-GAAP adjusted EBITDA	$	217,000		$	225,000

SUPPLEMENTAL 2013 EARNINGS PER SHARE GUIDANCE
RECONCILIATION OF SELECTED NON-GAAP MEASURES TO GAAP MEASURES
(UNAUDITED)

	Guidance Range for
	Twelve Months Ending
In 000s, except per share data	December 31, 2013
	(Low)			(High)

Net Income	$	22,900		$	26,600

EPS - diluted		0.38			0.44

Pre-tax non-cash, acquisition-related intangible amortization and depreciation		1.06			1.06
Pre-tax non-cash, share-based compensation		0.26			0.26
Pre-tax acquisition and integration-related expenses		0.16			0.16

Tax effect on pre-tax adjustments ^b		(0.59	)		(0.59	)

Non-GAAP adjusted EPS - diluted ^c	$	1.26		$	1.32

Fully diluted weighted average shares outstanding		61,000			61,000

SUPPLEMENTAL NON-GAAP CONTRACTED REVENUE ESTIMATES
(UNAUDITED)

	Twelve Months Ended
In Millions	June 30,			March 31,			Dec. 31,		Sept. 30,		June 30,
	2013			2013			2012		2012		2012

SCM segment	$	378.4		$	374.0		$	364.7	$	370.6	$	373.1
RCM segment		238.4			227.7			236.0		232.8		230.3
Total	$	616.8		$	601.7		$	600.7	$	603.4	$	603.4



SUPPLEMENTAL REPORTING OF SHARE-BASED COMPENSATION
EXPENSE INCLUDED IN OPERATING EXPENSES
(UNAUDITED)

In 000s	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2013			2012			2013		2012
Amount of share-based compensation included in:
Cost of revenue	$	1,463		$	362		$	2,176	$	863
Product development expense		225			(4	)		343		89
Selling & marketing expense		590			329			969		787
General & administrative expense		1,733			1,769			3,934		3,276

Total	$	4,011		$	2,456		$	7,422	$	5,015


SUPPLEMENTAL REPORTING OF FREE CASH FLOW
RECONCILIATION OF SELECTED NON-GAAP MEASURES TO GAAP MEASURES
(UNAUDITED)

In 000s	Six Months Ended
	June 30,
	2013			2012

Cash provided by operating activities	$	67,584		$	62,693
Purchases of property, equipment and software		(5,328	)		(7,892	)
Capitalized software development costs		(18,861	)		(20,208	)

Non-GAAP free cash flow	$	43,395		$	34,593

These non-GAAP financial measures may have limitations as analytical tools and should not be considered in isolation or as a substitute for analysis of the Company’s results as reported under GAAP. The Company compensates for such limitations by relying primarily on the Company’s GAAP results and using non-GAAP financial measures only supplementally. Where possible, the Company provides reconciliations of non-GAAP financial measures to the most directly comparable GAAP measures. Investors are encouraged to carefully review those reconciliations. In addition, because these non-GAAP measures are not measures of financial performance under GAAP and are susceptible to varying calculations, these measures, as defined by the Company, may differ from and may not be comparable to similarly titled measures used by other companies.

Gross fees include gross administrative fees the Company receives pursuant to its vendor contracts and all other fees the Company receives from clients. The Company's revenue share obligation represents the portion of the gross administrative fees the Company is contractually obligated to share with certain of its GPO clients. Net administrative fees (a GAAP measure) are the Company's gross administrative fees net of its revenue share obligation. Total net revenue (a GAAP measure) reflects the Company's gross fees net of its revenue share obligation. These non-GAAP measures assist management and the board of directors and may be helpful to investors in analyzing the Company's growth in its Spend and Clinical Resource Management segment given that administrative fees constitute a material portion of the Company's revenue and are paid to the Company by approximately 1,150 suppliers and other vendors contracted by its GPO, and that the Company's revenue share obligation constitutes a significant outlay to certain of its GPO clients.

The Company defines: EBITDA as net income (loss) before net interest expense, income tax expense (benefit), depreciation and amortization; and adjusted EBITDA as net income (loss) before net interest expense, income tax expense (benefit), depreciation and amortization and other non-recurring, non-cash or non-operating items. EBITDA and adjusted EBITDA are used by the Company to facilitate a comparison of its operating performance on a consistent basis from period to period and provides for a more complete understanding of factors and trends affecting our business. These measures assist management and the board of directors and may be useful to investors in comparing the Company's operating performance consistently over time as it removes the impact of its capital structure (primarily interest charges and amortization of debt issuance costs), asset base (primarily depreciation and amortization) and items outside the control of the management team (taxes), as well as other non-cash (purchase accounting adjustments and imputed rental income) and non-recurring items, from the Company’s operational results. Adjusted EBITDA also removes the impact of non-cash share-based compensation expense and certain acquisition-related charges. EBITDA and adjusted EBITDA are not measures of liquidity under GAAP, or otherwise, and are not alternatives to cash flow from continuing operating activities.

The Company defines adjusted net income as earnings excluding non-cash acquisition-related intangible amortization and non-recurring expense items on a tax-adjusted basis, non-cash tax-adjusted shared-based compensation expense and certain acquisition and integration-related expenses on a tax-adjusted basis and diluted adjusted EPS as earnings per share excluding non-cash acquisition-related intangible amortization and non-recurring expense items on a tax-adjusted basis, non-cash tax-adjusted shared-based compensation expense and certain acquisition and integration-related expenses on a tax-adjusted basis. Adjusted net income and diluted adjusted EPS are not measures of liquidity under GAAP, or otherwise, and are not alternatives to cash flow from continuing operating activities. Use of this measure for this purpose allows management and the board of directors to analyze the Company’s operating performance on a consistent basis by removing the impact of certain non-cash and non-recurring items from our operations, and by rewarding organic growth and accretive business transactions. As a significant portion of senior management’s incentive based compensation has historically been based on the achievement of certain diluted adjusted EPS growth over time, investors may find such information useful.

The Company defines free cash flow as cash provided by operating activities less purchases of property, equipment and software and capitalized software development costs. Management believes free cash flow is an important measure because it represents the cash that the Company is able to generate after spending capital on infrastructure to maintain its business and investing in new and upgraded products and services to support future growth. Free cash flow is important because it allows the Company to pursue opportunities that are intended to enhance shareholder value, which could include debt reduction, share repurchases, partnerships, alliances and acquisitions, and/or dividend payments. The Company's definition of free cash flow does not consider non-discretionary cash payments, such as debt.

Contracted revenue is a forward-looking operating measure used by management and the board of directors to better understand revenue growth trends within the Company's business segments as it reflects the Company’s current estimate of contractually committed revenue to be generated under existing client contracts in the forward 12-month period. Such information may be useful to investors in their analysis of the Company's revenue growth trends. A reconciliation to the most directly comparable GAAP measure cannot be performed without unreasonable effort.

Exhibit Number		Description

99.1		Press Release, dated July 31, 2013.


		This exhibit is furnished pursuant to Item 2.02 and shall not be deemed to be “filed.”

	MedAssets, Inc.


July 31, 2013	By:	/s/ Charles O. Garner
		Name: Charles O. Garner

		Title: Executive Vice President and Chief Financial Officer

Exhibit No.	Description

99.1	Press release dated July 31, 2013.

($ in millions, except per share)	FY 2013	Y-Y % change
Net Revenue:
SCM segment	$416.0 - 424.0	5.7 - 7.7%
RCM segment	255.0 - 261.0	3.4 - 5.9
Total Net Revenue	673.0 - 683.0	5.1 - 6.7
Non-GAAP adjusted EBITDA	217.0 - 225.0	4.7 - 8.5%
GAAP EPS – diluted	0.38 - 0.44	nm
Non-GAAP adjusted EPS – diluted	$1.26 - 1.32	11.5 -16.8%

Time/Date:		5:00 p.m. ET today, Wednesday, July 31, 2013
Phone:		855-410-0553 (or 646-583-7389 for international/local callers), PIN code 816274
Webcast:		http://ir.medassets.com, “Events & Presentations” page; Archive will be available for at least 30 days
Replay:		Call 877-764-8714 or 646-583-7395 (PIN code 338589)

	MedAssets, Inc.

	(Exact name of registrant as specified in its charter)

	Not Applicable

	(Former name or former address, if changed since last report)